RUNX1 is a member of the core-binding factor family of transcription factors and is
indispensable for the establishment of definitive hematopoiesis in vertebrates. RUNX1 is …

Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …

Background Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-
ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of …

Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy and/or
radiation administered for a primary condition, typically a malignant disease, solid organ …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The
pathophysiology of this disease is just beginning to be understood at the cellular and …

In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

Abstract Since 2001, the World Health Organization classification for hematopoietic and
lymphoid neoplasms has provided a framework for defining acute leukemia (AL) subtypes …

Background The full complement of DNA mutations that are responsible for the
pathogenesis of acute myeloid leukemia (AML) is not yet known. Methods We used …

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. AML is
a heterogeneous malignancy characterized by distinct genetic abnormalities. Recent …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized
by the proliferation and aberrant differentiation of immature clonal myeloid cells. The …